TG Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael S. Weiss
- Full Time Employees
- 352
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2 Gansevoort Street Morrisville NY United States of America 10014
- IPO Date
- May 3, 2010
- CIK
- 0001001316
- Website
- tgtherapeutics.com
- Similar Companies
- Business
- TG Therapeutics, Inc. operates as a commercial-stage biopharmaceutical firm, strategically engaged in acquiring, developing, and bringing to market innovative therapies for B-cell mediated autoimmune conditions and various hematologic cancers. The company's primary commercial asset is BRIUMVI (ublituximab-xiiy), a distinct glycoengineered anti-CD20 monoclonal antibody. BRIUMVI has received regulatory approvals in the United States, Europe, and other territories for managing relapsing forms of multiple sclerosis in adults, encompassing clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Its unique value proposition includes its rapid one-hour infusion administration, given twice annually following the initial dose, offering enhanced patient convenience. Beyond its marketed product, the company maintains an active development pipeline featuring several investigational compounds. This includes a subcutaneous formulation of ublituximab, currently in a Phase 3 trial (ENHANCE) for relapsing multiple sclerosis, aimed at further improving patient experience. Other candidates in early-stage clinical development (Phase 1) target B-cell disorders, such as TG-1701, an oral Bruton's tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific CD47 and CD19 antibody. Additionally, Azer-Cel, an allogeneic CD19 CAR T-cell therapy, is under investigation for B-cell malignancies. TG Therapeutics has reported robust financial performance, with significant revenue growth driven by BRIUMVI sales, and has recently completed and authorized substantial share repurchase programs. The firm has also secured a national contract with the U.S. Department of Veterans Affairs for BRIUMVI as a preferred treatment for relapsing multiple sclerosis. Collaborative agreements, such as the ex-U.S. commercialization partnership with Neuraxpharm Group for BRIUMVI, underscore its strategic approach to expanding market reach. Incorporated in 1993, TG Therapeutics, Inc. is headquartered in Morrisville, North Carolina.
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?
TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event
TG Therapeutics Stock Surges After Drug Trial Update
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial